Atyr PHARMA (NASDAQ:ATYR) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Atyr PHARMA (NASDAQ:ATYR) posted its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05, Zacks reports.

Atyr PHARMA Stock Up 12.4 %

ATYR stock traded up $0.44 during trading on Thursday, hitting $3.99. 1,826,496 shares of the stock traded hands, compared to its average volume of 1,288,022. The stock has a market cap of $334.93 million, a price-to-earnings ratio of -4.24 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The firm’s 50 day moving average is $3.65 and its two-hundred day moving average is $3.04.

Wall Street Analyst Weigh In

ATYR has been the topic of several recent analyst reports. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Leerink Partners started coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price for the company. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.